Incompatibility of connexin 40 and 43 Hemichannels in gap junctions between mammalian cells is determined by intracellular domains.

Murine connexin 40 (Cx40) and connexin 43 (Cx43) do not form functional heterotypic gap junction channels. This property may contribute to the preferential propagation of action potentials in murine conductive myocardium (expressing Cx40) which is surrounded by working myocardium, expressing Cx43. When mouse Cx40 and Cx43 were individually expressed in cocultured human HeLa cells, no punctate immunofluorescent signals were detected on apposed plasma membranes between different transfectants, using antibodies specific for each connexin, suggesting that Cx40 and Cx43 hemichannels do not dock to each other. We wanted to identify domains in these connexin proteins which are responsible for the incompatibility. Thus, we expressed in HeLa cells several chimeric gene constructs in which different extracellular and intracellular domains of Cx43 had been spliced into the corresponding regions of Cx40. We found that exchange of both extracellular loops (E1 and E2) in this system (Cx40*43E1,2) was required for formation of homotypic and heterotypic conductive channels, although the electrical properties differed from those of Cx40 or Cx43 channels. Thus, the extracellular domains of Cx43 can be directed to form functional homo- and heterotypic channels. Another chimeric construct in which both extracellular domains and the central cytoplasmic loop (E1, E2, and C2) of Cx43 were spliced into Cx40 (Cx40*43E1,2,C2) led to heterotypic coupling only with Cx43 and not with Cx40 transfectants. Thus, the central cytoplasmic loop of Cx43 contributed to selectivity. A third construct, in which only the C-terminal domain (C3) of Cx43 was spliced into Cx40, i.e., Cx40*43C3, showed neither homotypic nor heterotypic coupling with Cx40 and Cx43 transfectants, suggesting that the C-terminal region of Cx43 determined incompatibility.

Invertebrate epithelial Na+ channels: amiloride-induced current-noise in crab gill.

Epithelial sheets (including cuticle) from posterior gills of the freshwater-adapted euryhaline crab Eriocheir sinensis were obtained according to the method of Schwarz and Graszynski ((1989) Comp. Biochem. Physiol. 92A, 601-604; (1989) Verh. Dtsch. Zool. Ges. 82, 211 and (1989) Arch. Int. Physiol. Biochim. 97, C45). With external NaCl-saline, the outward-directed short-circuit current (Isc) could hardly be influenced by external amiloride up to 100 mumol/l but was, on the contrary, strictly dependent on apical Cl- (Onken, Graszynski and Zeiske (1991) J. Comp. Physiol. B 161, 293-301). In absence of external chloride an inward-directed, amiloride-inhibitable Isc was observed which depended on external Na+ (thus, Isc approximately INa) in a two-step, saturating mode. The Isc-block by amiloride obeyed saturation kinetics (half-maximal at less than or equal to 1 mumol/l, suggesting apical Na(+)-channels). Only for Na+ concentrations below 100 mmol/l we found an indication for a competitive interaction between Na+ and amiloride at the channel. Current fluctuation analysis revealed the presence of an amiloride-induced relaxation (Lorentzian) component in the Isc-noise (so-called 'blocker-noise'). The Lorentzian parameter-shifts with increasing amiloride concentration indicate first-order kinetics of the blocker with its apical receptor. Using a 'two-state' blocking model we calculated, for amiloride concentrations between 2 and 5 mumol/l, a mean single-channel current of 0.46 pA and a mean channel density of 250.10(6) cm-2.

Characterization of gap junction genes expressed in F9 embryonic carcinoma cells: molecular cloning of mouse connexin31 and -45 cDNAs.

In an attempt to characterize connexin genes expressed early in mouse development we screened a cDNA library from mouse F9 embryonic carcinoma cells with mouse connexin37 cDNA and mouse connexin31.1 genomic DNA under low stringency of hybridization. We detected 5 different connexin cDNAs coding for mouse connexins31, -31.1, -32, -43, and -45 (reviewed in Willecke et al., Eur. J. Cell Biol. 56, 1-7 (1991)). Here we describe characterization of mouse connexin31 cDNA coding for a protein of 270 amino acids (Mr 30,905) that shows 8 amino acid exchanges compared to its rat analog recently deduced from its genomic sequence. Mouse connexin45 cDNA codes for a protein of 396 amino acids (Mr 45,671) that exhibits 84% amino acid identity compared to its chick analog described. Cx31 and Cx45 are coded for by single genes in the mouse genome. After Northern blot hybridization, we detected two Cx31 transcripts of 1.9 and 2.3 kb in total mouse RNA from skin, keratinocyte-derived cell lines, and in testis. Cx45 cDNA hybridized to a 2.2 kb mRNA in lung, brain, skin, heart, and intestine. This transcript showed maximal expression in adult lung and in embryonic tissues tested (brain, skin, kidney) where it was at least 40-fold more abundant than in the corresponding adult tissues.

Two cases of giant intracerebral aneurysm simulating neoplasm on ct scan; one with coexistent chronic subdural hematoma.

Two cases of giant intracerebral aneurysm are presented. Both exhibit increased absorption values in a circumferential configuration peripherally after the administration of contrast material. In addition, one case demonstrates a coexistent contralateral chronic subdural hematoma. No previous example of intracranial aneurysm exhibiting this configuration on computed tomography has been described in the literature. The operative, computed tomographic, radionuclide and angiographic findings are described and the differential diagnosis discussed.

Liquid-solid chromatographic determination of 6-demethylgriseofulvin in urine.

A specific and quantitative liquid-solid chromatographic method for the determination of 6-demethylgriseofulvin in human urine is reported. The method consists of extraction into an organic solvent, addition of internal standard, and analysis by liquid-solid chromatography using a UV detector. Griseofulvin, if present, can be determined simultaneously. The sensitivity of the method is 6 mug/ml of urine. Total 6-demethylgrisefulvin is determined after hydrolysis of the glucuronide conjugate with glucuronidase-sulfatase enzyme solution. The method is well suited for the analysis of a large number of samples.

GLC determination of griseofulvin in human plasma.

A specific and quantitative GLC method for the determination of griseofulvin in human plasma is described. The method involves extraction with ether, evaporation, addition of the internal standard dissolved in benzene, and GLC analysis using an electron-capture detector. The sensitivity of the method is 0.05 mug/ml of plasma. The results obtained with this specific GLC method were compared with the results obtained with the more frequently used spectroflurometric method by analyzing duplicate plasma samples obtained from 12 subjects following a single dose of griseofulvin. It was deduced that the 30% higher plasma levels obtained spectrofluormetrically were due to the coextraction and presence of the metabolite 6-demethylgriseofulvin in the assay solutions.

Enterohepatic circulation of radioactivity following an oral dose of [14C]temazepam in the rat.

The enterohepatic circulation of radioactive material after administering [14C]temazepam was evaluated in three sets of male Wistar strain rats connected in pairs by bile duct-duodenum cannulae. After a single oral dose (10 mg kg-1) to the donor rat, the excretion of radioactivity in the urine and faeces of both rats and in the bile of the recipient rat was determined. Mean total recovery of the administered radioactivity was 92.2%. Based on the amount remaining in the donor rat (gastrointestinal tract and faeces), 81.7% of the dose was absorbed by the donor. The total amount recovered from the recipient, 69.4% of original dose (85.1% of donor's absorbed dose), represented the amount excreted in the donor's bile. Similarly, 54.1% of the original dose (77.9% of the transferred biliary excretion from donor) was reabsorbed by the recipient, and the biliary excretion from this animal (45.9% original dose) accounted for 86.% of the amount reabsorbed.

Effect of food, fluid and dosage form on the absorption of 52-522, a potential antianxiety agent, in the dog.

The absorption of 52-522 in the dog was studied by measuring blood concentrations of radioactivity after single oral doses of [14C] 52-522 in a capsule with and without water, also as a food-drug mixture, and a solution in polyethylene glycol 400. Absorption was rapid, and its rate moderate with no significant differences in peak times among treatments. The extent of absorption was lowest after the capsulated [14C] 52-522. The solution dose gave elevated blood concentrations, that were statistically significantly different when compared with the capsules. Hence, it appears that the absorption of [14C] 52-522 is governed by the degree of dispersion of drug in the dosage form.

Pharmacokinetics and metabolism of temazepam in man and several animal species.

1 Absorption, excretion and detoxification of temazepam were investigated in man, mouse, rat and dog. Considerable interspecies variation was apparent with respect to excretion and metabolite patterns in blood and urine. Animal species were exposed to equal or greater concentrations of all the metabolites occurring in man. 2 Pharmacokinetics of temazepam in man were investigated in a single dose study at two dose levels, and in a multiple dose study. The results of both studies were analyzed and interpreted with the help of compartmental models. Values were obtained for excretion pattern (0-infinity), half lives (1.95, 0.5, 10.0 and 1.9 h), amounts in all compartments, and for steady-state conditions. 3 The bioavailability of the hard gelatin capsule dosage form was compared with that of a suspension serving as the ideal dosage form, and found to be acceptable.

Pharmacokinetics of pindolol in humans and several animal species.

The absorption, distribution, detoxification, and excretion of pindolol were investigated in mice, rats, dogs, rhesus monkeys, and humans. The absorption was very good in all species; however, the quantitative composition of the final excretion products was unique for each species. Considerable interspecies variation was also apparent with respect to excretion patterns. The pharmacokinetics of pindolol in humans was investigated in single- and multiple-dose studies. All results were in agreement with a three-compartment model. The absorption was rapid and a first-pass effect of 12% to 25% of the dose (mean 20%) was calculated. The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours. The pharmacokinetic parameters obtained in normal volunteers were compared with corresponding values obtained in patients with hypertension, renal insufficiency, or liver impairment. Results in these patients were not significantly different. The bioavailability interaction was investigated with drugs often coadministered with a beta blocker. No drug-drug interaction was found with hydralazine, hydrochlorothiazide, coumarin, or aspirin. Pindolol coadministration resulted in a possible lowering of digoxin levels. The bioavailability of the tablet dosage forM proposed for marketing was compared to that of a solution and found to be optimal.

Chromosomal assignments of mouse genes for connexin 50 and connexin 33 by somatic cell hybridization.

The 12 known connexin genes coding for the subunit proteins of the gap junction channels and related in nucleotide sequence are widely dispersed in the mouse genome. By using a series of mouse X Chinese hamster somatic cell hybrids and molecular probes of murine connexin genes, we have assigned the connexin 50 gene to mouse chromosome 3. The connexin 33 gene has been mapped to the X chromosome, thus confirming the previous chromosomal assignment of this gene based on interspecific back-cross mapping.

Chromosomal assignments of mouse connexin genes, coding for gap junctional proteins, by somatic cell hybridization.

The connexin genes Cx31 and Cx45 coding for proteins of gap junctional subunits have been assigned to mouse chromosomes 4 and 11 by Southern blot hybridization of specific gene probes to DNA from mouse x Chinese hamster somatic cell hybrids. In addition, our results confirm the recent assignment of mouse connexin genes Cx26, Cx32, Cx37, Cx40, Cx43, and Cx46 to mouse chromosomes 14, X, 4, 3, 10, and 14, respectively, by analysis of interspecific backcrosses and by somatic cell hybridization. Our assignment of the Cx31 gene to mouse chromosome 4 locates the fourth connexin gene on this mouse chromosome to which the genes for Cx31.1, Cx37, and Cx30.3 have previously been assigned. Interestingly three of them (coding for Cx31, Cx31.1, and Cx30.3) are preferentially expressed in skin. Possibly some of the connexin genes clustered on mouse chromosome 4 may be regulated coordinately.

The hepatocyte-specific phenotype of murine liver cells correlates with high expression of connexin32 and connexin26 but very low expression of connexin43.

This investigation was initiated in order to find out whether expression of the hepatocyte-specific phenotype is accompanied by expression of certain connexin genes coding for gap junctional protein subunits. Several clones of mouse embryonic hepatocytes immortalized in serum-free MX83 medium by infection with recombinant retrovirus-expressed transcripts for connexin32, connexin26, albumin, alpha-fetoprotein, tyrosine aminotransferase, as well as aldolase A and B, at more than half of the levels found in primary mouse hepatocytes. In addition the immortalized hepatocyte clones contained low levels of connexin43 mRNA of which only trace amounts were detected in primary embryonic mouse hepatocytes and in rat liver. Two of the immortalized hepatocyte clones were shifted from serum-free MX83 medium to Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum and, after 2, 14, or 180 days, back to MX83 medium. We found that expression of connexin32 and connexin26 mRNAs as well as transcripts of other liver-specific proteins was reversibly decreased in serum-containing medium, whereas the expression level of connexin43 transcripts was increased in serum-containing DMEM compared to serum-free MX83 medium. The expression levels of connexin26, connexin32, or connexin43 mRNAs were altered by the addition of fetal calf serum or arginine or by the absence of hydrocortisone in MX83 medium, all of which contributed to the shift in phenotype. Furthermore several dedifferentiated cell lines derived from rat or mouse liver and cultivated in serum-containing medium were found to express little connexin32 or connexin26 mRNA but relatively high levels of connexin43 mRNA.

Biotransformation of mazindol. I. Isolation and identification of some metabolites from rat urine.

Three metabolites of tritium-labeled mazindol were isolated from rat urine by the inverse isotope-dilution technique in which the labeled metabolites were synthesized by a second, smaller group of rats. These metabolites were isolated by Amberlite XAD-2 chromatography and silica gel column and preparative thin-layer chromatography. The major metabolite (II) was shown by mass spectrometry of its trimethylsilyl derivative. NMR spectroscopy, and degradation studies to be 5-(p-chlorophenyl)-2,5-dihydro-5-hydroxy-3H-imidazol(2,1-a)isoindol-3-one. A comparison of its mass spectrum with that of an authentic sample prepared from 1-(p-chlorophenyl)-3-ethoxy-1-methoxy-1H-isoindole and glycine ethyl ester confirmed the assignment. Metabolite III was shown by its mass spectrum, NMR spectrum, degradation, and analogy with metabolite II to be 5-(p-chlorophenyl)-2,5-dihydro-2,5-dihydroxy-3H-imidazo (2,1-a)isoindol-3-one. Only a small amount of metabolite IV was isolated as an artifact, 3-(p-chlorophenyl)-2-glycyl-3-methoxy-1-isoindolinone, as shown by its mass spectrum and degradation to 2-(p-chlorobenzoy)benzoic acid. The metabolite IV is believed to be the corresponding 3-hydroxy compound. Synthesis of IV by base-catalyzed hydrolysis of metabolite II supports the structural assignment. In addition, the facile conversion of synthetic IV into the corresponding 3-methoxy derivative by acidic methanol was also observed.

The biotransformation of fluproquazone in man and several animal species.

The biotransformation of 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) has been investigated in man, mouse, rat, rabbit, and dog. Single oral doses of 3H-fluproquazone were administered to the animals (15 mg/kg). Human volunteers received 100 mg 3H-fluproquazone t.i.d. for 5 days (3.8 mg/kg). Two potential metabolites were synthesized: 4-(p-fluorophenyl)-1,2-dihydro-1-isopropyl-2-oxo-7-quinazolinecarboxylic acid (4) and 4-(p-fluorophenyl)-7-hydroxymethyl-1-isopropyl-2(1H)-quinazolinone (11). The human urinary metabolites of fluproquazone were separated and purified by a combination of extractions and liquid chromatography on reversed-phase columns, and structures were proposed on the basis of identify with known standards, mass spectral data, and retention time comparison. Definitive structures were assigned to five metabolites. Fluproquazone and its metabolites were characterized and quantitated in the blood, urine, and feces of man, mouse, rat, rabbit, and dog by high-pressure liquid chromatography coupled to a radioactivity monitor or by reverse isotope dilution analysis. Significant quantities of fluproquazone were noted in the blood of all species. The major circulating metabolite in blood at or near the peak of radioactivity was 11 in rat, mouse, and dog and 4 in man and rabbit. In all species analyzed, 4 was the major metabolite excreted in the urine and feces. In man the minor metabolites consisted of 11 as a conjugate and several phenolic derivatives also conjugated. The animals were exposed to the same major metabolite as man and each minor metabolite found in man, with the exception of a few very minor ones, was identified in at least one of the animal species. The metabolite pattern did not vary significantly among the 3 human subjects analyzed nor over the 5-day dosing period. Two biotransformation pathways were identified. The major pathway was sequential oxidation with or without conjugation of the 7-methyl group; aromatic hydroxylation and conjugation was a minor pathway.

Two gap junction genes, connexin 31.1 and 30.3, are closely linked on mouse chromosome 4 and preferentially expressed in skin.

Two new gap junction genes isolated from the mouse genome code for connexin homologues of 271 and 266 amino acids, designated here Cx31.1 and Cx30.3, respectively. The two open reading frames, oriented in the same direction, are only 3.4 kb apart on mouse chromosome 4. Within the connexin family, these two proteins are most closely related to one another (70% amino acid sequence identity) and to Cx31 (65 and 68% identity, respectively). Comparison of the Cx31.1 mouse gene with a Cx31.1 cDNA showed a similar genomic organization to that found with other members of the connexin gene family, i.e. the coding and 3'-untranslated regions are contained within a single exon, which is preceded by an intron, less than 25 bases upstream of the ATG start codon. Northern blot hybridization revealed highly tissue-specific coexpression of the 1.6-kb Cx31.1 mRNA and two Cx30.3 transcripts of 1.9- and 3.2-kb size, predominantly in skin and two related mouse keratinocyte cell lines. Minor levels of Cx31.1 mRNA were detected in testis. Microinjection of Cx30.3, but not Cx31.1 cRNA, into Xenopus oocyte pairs induced formation of functional gap junction channels with unique voltage-gated parameters compared to other connexins expressed similarly.

Molecular cloning and functional expression of mouse connexin-30,a gap junction gene highly expressed in adult brain and skin.

A new gap junction gene isolated from the mouse genome codes for a connexin protein of 261 amino acids. Because of its theoretical molecular mass of 30.366 kDa, it is named connexin-30. Within the connexin gene family, this protein is most closely related to connexin-26 (77% amino acid sequence identity). The coding region of mouse connexin-30 is uninterrupted by introns and is detected in the mouse genome as a single copy gene that is assigned to mouse chromosome 14 by analysis of mouse x hamster somatic cell hybrids. Abundant amounts of connexin-30 mRNA (two transcripts of 2.0 and 2.3 kilobase pairs) were found after 4 weeks of postnatal development in mouse brain and skin. Microinjection of connexin-30 cRNA into Xenopus oocytes induced formation of functional gap junction channels that gated somewhat asymmetrically in response to transjunctional voltage and at significantly lower voltage (Vo = +38 and -46 mV) than the closely homologous connexin-26 channels (Vo = 89 mV). Heterotypic pairings of connexin-30 with connexin-26 and connexin-32 produced channels with highly asymmetric and rectifying voltage gating, respectively. This suggests that the polarity of voltage gating and the cationic selectivity of connexin-30 are similar to those of its closest homologue, connexin-26.